atovaquone

GPTKB entity

Statements (33)
Predicate Object
gptkbp:instanceOf gptkb:chemical_compound
antiviral drug
antineoplastic agent
gptkbp:approvalYear 1992
gptkbp:ATCCode P01AX06
gptkbp:bioavailability variable, increased with fatty food
gptkbp:brand gptkb:Mepron
Malarone (with proguanil)
gptkbp:CASNumber 95233-18-4
gptkbp:chemicalFormula C22H19ClO3
gptkbp:combines gptkb:proguanil
gptkbp:contraindication hypersensitivity to atovaquone
gptkbp:discoveredBy GlaxoSmithKline
gptkbp:eliminationHalfLife 2–3 days
gptkbp:excretion feces
https://www.w3.org/2000/01/rdf-schema#label atovaquone
gptkbp:IUPACName 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction inhibits mitochondrial electron transport
gptkbp:meltingPoint 220–221 °C
gptkbp:metabolism minimal
gptkbp:molecularWeight 366.84 g/mol
gptkbp:pregnancyCategory C (US)
gptkbp:routeOfAdministration oral
gptkbp:sideEffect nausea
diarrhea
headache
rash
gptkbp:usedFor treatment of malaria
treatment of Pneumocystis jirovecii pneumonia
treatment of toxoplasmosis
gptkbp:bfsParent gptkb:Pneumocystis_pneumonia
gptkbp:bfsLayer 5